A negatively charged glycosaminoglycan is provided for use as a medicament for the treatment of cancer. A combined administration of a negatively charged glycosaminoglycan is provided in which the glycosaminoglycan is characterised by the absence of the terminal pentasaccharide of Heparin, and an inhibitor of the MAPK/ERK pathway. A combined administration of a glycosaminoglycan and a MAPK/ERK pathway inhibitor is provided as a medicament for the treatment of cancer types that exhibit a resistance towards a single MAPK/ERK pathway inhibitor treatment.

The present invention relates to the field of nutraceuticals, and in particular to nutraceuticals comprising sulfated polysaccharides, Astragalus polysaccharides, resveratrol, and combinations thereof. These compositions find use in inducing physiological responses such, decreasing body fat, increasing lean body mass, alleviating the symptoms of colds, preventing the onset of colds, increasing energy, increasing the feeling of well-being in subjects, and improving skin tone and appearance.

The present invention relates to the field of nutraceuticals, and in particular to nutraceuticals comprising sulfated polysaccharides, Astragalus polysaccharides, resveratrol, and combinations thereof. These compositions find use in inducing physiological responses such, decreasing body fat, increasing lean body mass, alleviating the symptoms of colds, preventing the onset of colds, increasing energy, increasing the feeling of well-being in subjects, and improving skin tone and appearance.

The present invention relates to the field of nutraceuticals, and in particular to nutraceuticals comprising sulfated polysaccharides, Astragalus polysaccharides, resveratrol, and combinations thereof. These compositions find use in inducing physiological responses such, decreasing body fat, increasing lean body mass, alleviating the symptoms of colds, preventing the onset of colds, increasing energy, increasing the feeling of well-being in subjects, and improving skin tone and appearance.

The present disclosure relates to pharmaceutical compositions comprising PTEN inhibitors and methods of treating or preventing bone marrow loss in subjects in subjects in need thereof. The compositions and methods of this disclosure are useful in treating or preventing bone marrow loss associated with exposure to nuclear radiation or chemotherapeutic treatment.

Provided are pharmaceutical compositions comprising a sulphated polysaccharide and a shear-thinning fluid gel. The sulphated polysaccharide may, by way of example, be selected from the group consisting of: a dextran sulphate having an average molecular weight of 10,000 Da or less; heparan sulphate; fucoidan; poligeenan; furcellaran; and a carrageenan. The shear-thinning fluid gel may comprise a microgel particle forming polymer, suitably selected from one or more of the following groups: gellans; alginates; carrageenans; agarose; chitosan; pectin; agarose; agar or gelatin. The compositions disclosed may be used for the prevention and/or treatment of glaucoma. These compositions may be used for the inhibition or reduction of fibrosis. The invention also relates to the medical uses of sulphated polysaccharides, and the medical uses of shear-thinning fluid gels.

Provided are pharmaceutical compositions comprising a sulphated polysaccharide and a shear-thinning fluid gel. The sulphated polysaccharide may, by way of example, be selected from the group consisting of: a dextran sulphate having an average molecular weight of 10,000 Da or less; heparan sulphate; fucoidan; poligeenan; furcellaran; and a carrageenan. The shear-thinning fluid gel may comprise a microgel particle forming polymer, suitably selected from one or more of the following groups: gellans; alginates; carrageenans; agarose; chitosan; pectin; agarose; agar or gelatin. The compositions disclosed may be used for the prevention and/or treatment of glaucoma. These compositions may be used for the inhibition or reduction of fibrosis. The invention also relates to the medical uses of sulphated polysaccharides, and the medical uses of shear-thinning fluid gels.

Disclosed herein are methods for prophylactic treatment of acute coronary syndrome (ACS) comprising administering, by inhalation, an effective amount of a pharmaceutical composition comprising at least one anticoagulant or antiplatelet agent to a subject in need thereof, wherein the anticoagulant or antiplatelet agent first enters the heart via the left atrium.

Disclosed herein are methods for prophylactic treatment of acute coronary syndrome (ACS) comprising administering, by inhalation, an effective amount of a pharmaceutical composition comprising at least one anticoagulant or antiplatelet agent to a subject in need thereof, wherein the anticoagulant or antiplatelet agent first enters the heart via the left atrium.

Compositions and methods of treating COVID-19 are disclosed. The compositions comprise heparin and/or one or more other negatively charged molecules.